Endothelin-1 Promotes Ca2+ Antagonist-Insensitive Coronary Smooth Muscle Contraction Via Activation of ε-Protein Kinase C

Hypertension

Volumn 43, Issue 4, 2004, Pages 897-904

  McNair, Lashonn L ^b   Salamanca, Daisy A ^b   Khalil, Raouf A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

Calcium; Endothelin; Protein kinases

Indexed keywords

CALCIUM; CALCIUM ANTAGONIST; CALPHOSTIN C; DILTIAZEM; ENDOTHELIN 1; ENZYME ACTIVATOR; ENZYME ANTIBODY; FURA 2; PEPTIDE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE; PROTEIN KINASE C ALPHA; PROTEIN KINASE C EPSILON; PROTEIN KINASE C EPSILON V1 INHIBITORY PEPTIDE; PROTEIN KINASE C EPSILON V2 INHIBITORY PEPTIDE; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; CORONARY ARTERY SPASM; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; INTRACELLULAR TRANSPORT; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SWINE; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; WESTERN BLOTTING;

ANIMALS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CORONARY VASOSPASM; CORONARY VESSELS; DILTIAZEM; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; ENDOTHELIN-1; ENZYME ACTIVATION; ENZYME INHIBITORS; MALE; MUSCLE, SMOOTH, VASCULAR; NAPHTHALENES; PEPTIDE FRAGMENTS; PROTEIN KINASE C; PROTEIN KINASE C-EPSILON; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SWINE; TETRADECANOYLPHORBOL ACETATE; VASOCONSTRICTION; VERAPAMIL;

EID: 1642419557     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000118520.92686.3b     Document Type: Article

References (45)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:310-318.
2. Kawano H, Fujii H, Motoyama T, Kugiyama K, Ogawa H, Yasue H. Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography. Am J Cardio. 2000;85:26-30.
3. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
4. Schiffrin EL, Touyz RM. Vascular biology of endothelin. J Cardiovasc Pharmacol. 1998;32:S2-S13.
5. Matsuyama K, Yasue H, Okumura K, Saito Y, Nakao K, Shirakami G, Imura H. Increased plasma level of endothelin-1-like immunoreactivity during coronary spasm in patients with coronary spastic angina. Am J Cardiol. 1991;68:991-995.
6. Artigou JY, Salloum J, Carayon A, Lechat P, Maistre G, Isnard R, Komajda M, Legrand JC, Grosgogeat Y. Variations in plasma endothelin concentrations during coronary spasm. Eur Heart J. 1993;14:780-784.
7. Toyo-oka T, Aizawa T, Suzuki N, Hirata Y, Miyauchi T, Shin WS, Yanagisawa M, Masaki T, Sugimoto T. Increased plasma level of endothelin-1 and coronary spasm induction in patients with vasospastic angina pectoris. Circulation. 1991;83:701-703.
8. Wieczorek I, Haynes WG, Webb DJ, Ludlam CA, Fox KA. Raised plasma endothelin in unstable angina and non-Q wave myocardial infarction: relation to cardiovascular outcome. Br Heart J. 1994;72: 436-441.
9. Salomone OA, Elliott PM, Calvino R, Holt D, Kaski JC. Plasma immunoreactive endothelin concentration correlates with severity of coronary artery disease in patients with stable angina pectoris and normal ventricular function. J Am Coll Cardiol. 1996;28:14-19.
10. Zouridakis EG, Schwartzman R, Garcia-Moll X, Cox ID, Fredericks S, Holt DW, Kaski JC. Increased plasma endothelin levels in angina patients with rapid coronary artery disease progression. Eur Heart J. 2001;22: 1519-1520.
11. Takase H, Sugiyama M, Nakazawa A, Toriyama T, Hayashi K, Goto T, Sato K, Ikeda K, Ueda R, Dohi Y. Increased endogenous endothelin-1 in coronary circulation is associated with restenosis after coronary angioplasty. Can J Cardiol. 2003;19:902-906.
12. Igarashi Y, Aizawa Y, Tamura M, Ebe K, Yamaguchi T, Shibata A, Vasoconstrictor effect of endothelin on the canine coronary artery: is a novel endogenous peptide involved in regulating myocardial blood flow and coronary spasm? Am Heart J. 1989;118:674-678.
13. Kurihara H, Yamaoki K, Nagai R, Yoshizumi M, Takaku F, Satoh H, Inui J, Yazaki Y. Endothelin: a potent vasoconstrictor associated with coronary vasospasm. Life Sci, 1989;44:1937-1943.
14. Baird MG, Juneau M, Nadeau C, Clermont P, Chin C, Boulet AA, Efficacy and safety of evening administration of controlled-delivery diltiazem capsules in chronic stable angina patients. Am J Ther. 1995;2: 401-406.
15. Brogden RN, Benfield P, Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. Drugs. 1996; 51:792-819.
16. Jespersen CM, Verapamil in acute myocardial infarction. The rationales of the VAMI and DAVIT III trials, Cardiovasc Drugs Ther. 2000;14: 99-105.
17. Opie LH. Mechanisms whereby calcium channel antagonists may protect patients with coronary artery disease. Eur Heart J. 1997;18:A92-A104.
18. Kumar A, Chandna H, Santhanam V, Denes P. Refractory vasospasm with a malignant course. Clin Cardiol. 2000;23:127-130.
19. Silvestry FE, Kimmel SE. Calcium-channel blockers in ischemic heart disease. Curr Opin Cardiol. 1996;11:434-439.
20. Horowitz A, Menice CB, Laporte R, Morgan KG. Mechanisms of smooth muscle contraction. Physiol Rev. 1996;76:967-1003.
21. Khalil RA, van Breemen C. Mechanisms of calcium mobilization and homeostasis in vascular smooth muscle and their relevance to hypertension. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York, NY: Raven Press; 1995: 523-540.
22. 2+] determines myosin phosphorylation in agonist-stimulated swine arterial smooth muscle, Circ Res. 1988;63:593-603.
23. Pollock DM, Keith TL, Highsmith RF. Endothelin receptors and calcium signaling. FASEB J. 1995;9:1196-1204.
24. Schroeder AC, Imig JD, LeBlanc EA, Pham BT, Pollock DM, Inscho EW. Endothelin-mediated calcium signaling in preglomerular smooth muscle cells. Hypertension. 2000;35:280-286.
25. Kanashiro CA, Khalil RA. Signal transduction by protein kinase C in mammalian cells. Clin Exp Pharmacol Physiol. 1998;25:974-985.
26. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 1992;258:607-614.
27. 2+-independent isoforms of protein kinase C differentially translocate in smooth muscle. Am J Physiol. 1992;263:C714-C719.
28. Liou YM, Morgan KG. Redistribution of protein kinase C isoforms in association with vascular hypertrophy of rat aorta. Am J Physiol. 1994; 267:C980-C989.
29. Jiang MJ, Morgan KG. Intracellular calcium levels in phorbol ester-induced contractions of vascular muscle. Am J Physiol. 1987;253: H1365-H1371.
30. Khalil RA, van Breemen C. Sustained contraction of vascular smooth muscle: calcium influx or C-kinase activation? J Pharmacol Exp Ther. 1988;244:537-542.
31. Chen L, Hahn H, Wu G, Chen CH, Liron T, Schechtman D, Cavallaro G, Banci L, Guo Y, Bolli R, Dorn GW 2nd, Mochly-Rosen D. Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc Natl Acad Sci U S A. 2001;98:1114-11119.
32. Chen L, Wright LR, Chen CH, Oliver SF, Wender PA, Mochly-Rosen D. Molecular transporters for peptides: delivery of a cardioprotective epsilonPKC agonist peptide into cells and intact ischemic heart using a transport system, R(7). Chem Biol. 2001;8:1123-1129.
33. Dubyak GR, Kertesy SB. Inhibition of GTP gamma S-dependent phospholipase D and Rho membrane association by calphostin is independent of protein kinase C catalytic activity. Arch Biochem Biophys. 1997;341: 129-139.
34. Kobayashi E, Nakano H, Morimoto M, Tamaoki T. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun. 1989;159: 548-553.
35. Khalil RA, Morgan KG. Phenylephrine-induced translocation of protein kinase C and shortening of two types of vascular cells of the ferret. J Physiol. 1992;455:585-599.
36. i during inhibition of coronary smooth muscle contraction by 17β-estradiol, progesterone, and testosterone. J Pharmacol Exp Ther. 1999;291:44-52.
37. i in vascular smooth muscle cells of female rat. Am J Physiol Cell Physiol. 2000;278:C834-C844.
38. Nayler WG, Perry SE, Elz JS, Daly MJ. Calcium, sodium, and the calcium paradox. Circ Res. 1984;55:227-237.
39. i threshold for translocation of the alpha-protein kinase C isoform. Am J Physiol. 1994;266:C1544-C1551.
40. 2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985; 260:3440-3450.
41. 2+ entry during coronary artery contraction by vasoactive eicosanoids. Can J Physiol Pharmacol. 1998;76:1110-1119.
42. Kanashiro CA, Altirkawi KA, Khalil RA. Preconditioning of coronary artery against vasoconstriction by endothelin-1 and prostaglandin F2α during repeated downregulation of ε-protein kinase C. J Cardiovasc Pharmacol. 2000;35:491-501.
43. Hempel A, Maasch C, Heintze U, Lindschau C, Dietz R, Luft FC, Haller H. High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha. Circ Res. 1997;81(3):363-371.
44. Togashi H, Hirshman CA, Emala CW. Qualitative immunoblot analysis of PKC isoforms expressed in airway smooth muscle. Am J Physiol. 1997;272:L603-L607.
45. Gratton JP, Yu J, Griffith JW, Babbitt RW, Scotland RS, Hickey R, Giordano FJ, Sessa WC. Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat Med. 2003;9:357-363.